Investors & Media

Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia

– More than 3 million people in the US have severe hypertriglyceridemia – The CORE Phase 3 clinical study further expands Ionis’ late-stage pipeline and is the second Phase 3 clinical study in Ionis’ broad olezarsen development program – Olezarsen is one of Ionis’ wholly owned medicines the company

Read more
You are now leaving to visit